Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon

International Journal of Colorectal Disease

Volumn 22, Issue 9, 2007, Pages 1103-1108

  Tursi, Antonio ^a,e   Brandimarte, Giovanni ^b   Giorgetti, Gian Marco ^c   Elisei, Walter ^b   Aiello, Fabio ^d  

^a Lorenzo Bonomo Hospital   (Italy)

^b Cristo Re Hospital   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e NONE   (Italy)

Author keywords

Balsalazide; Diverticulitis; Follow up; Probiotics; Recurrence

Indexed keywords

ANTIINFLAMMATORY AGENT; BALSALAZIDE; BALZIDE; PROBIOTIC AGENT; RIFAXIMIN; UNCLASSIFIED DRUG; VSL3;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ADULT; AGED; ARTICLE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON DIVERTICULOSIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; MALE; MONOTHERAPY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS SALIVARIUS; SYMPTOMATOLOGY;

ACUTE DISEASE; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIFIDOBACTERIUM; DIVERTICULITIS, COLONIC; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; LACTOBACILLUS CASEI; MALE; MESALAMINE; MIDDLE AGED; PHENYLHYDRAZINES; PILOT PROJECTS; PROBIOTICS; RECURRENCE; TREATMENT OUTCOME;

EID: 34848822176     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-007-0299-6     Document Type: Article

References (34)

1. Almy TP, Howell DA (1980) Diverticular disease of the colon. N Engl J Med 302:324-331
2. Painter NS, Burkitt DP (1971) Diverticular disease of the colon: A deficiency disease of western civilization. Br Med J 2:450-454
3. Parks TG (1975) Natural history of diverticular disease of the colon. Clin Gastroenterol 4:53-69
4. Painter NS, Burkitt DP (1975) Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol 4:3-21
5. Berman LG, Burdick D, Heitzman ER, Prior JT (1968) A critical reappraisal of sigmoid peridiverticulitis. Surg Gynecol Obstet 127:481-491
6. Williams RA, Davis IP (1995) Diverticular disease of the colon. In: Haubrich WS, Schaffner F (eds) Bockus gastroenterology, 5th edn. Saunders, Philadelphia, pp 1637-1656
7. Tursi A, Brandimarte G, Daffinà R (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Dig Liver Dis 34:510-515
8. Ragunath K, Williams JG (2001) Review article: Balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther 15:1549-1554
9. Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC (2002) A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 16:61-68
10. Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD (2002) A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 16:69-77
11. Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, Crowe JP, Schofield KJ, Taylor MD (1998) Maintenance of remission of ulcerative colitis: A comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. Aliment Pharmacol Ther 12:1207-1216
12. Sanders ME (1999) Probiotics. Food Technol 53:67-77
13. Gionchetti P, Amadini C, Rizzello F, Venturi A, Palmonari V, Morselli C, Romagnoli R, Campieri M (2002) Probiotics-role in inflammatory bowel disease. Dig Liver Dis 34(Suppl 2):S58-S62
14. Isolauri E (2003) Probiotics for infectious diarrhoea. Gut 52:436-437
15. Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M (2002) Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 34(Suppl 2):S48-S53
16. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L et al (2002) Effect of different probiotic preparations on anti- Helicobacter pylori therapy-related side-effects: A parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 97:2744-2749
17. Frič P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15:313-315
18. Tursi A, Brandimarte G, Giorgetti GM, Elisei W (2006) Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: A prospective, randomised, open-label study. J Clin Gastroenterol 40:312-316
19. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M (1999) Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13:1103-1108
20. Lamanna A, Orsi A (1984) In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 11:365-367
21. Papi C, Ciaco A, Koch M, Capurso L (1995) Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 9:33-39
22. Chautems RC, Ambrosetti P, Ludwig A, Mermillod B, Morel P, Soravia C (2002) Long-term follow-up after first acute episode of sigmoid diverticulitis: IA surgery mandatory?: a prospective study of 118 patients. Dis Colon Rectum 45:962-966
23. Brandimarte G, Tursi A (2004) Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit 10(5):PI70-PI73
24. Shanahan F (2001) Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120:622-635
25. Giaccari S, Tronci S, Falconieri M, Ferrieri A (1993) Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur Rev Med Pharmacol Sci 15:29-34
26. Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E (1999) Immunity and probiotics. Immunol Today 20:387-390
27. Bengmark S (1998) Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 42:2-7
28. Borruel N, Casellas F, Antolin M, Llopis M, Carol M, Espíin E, Naval J, Guarner F, Malagelada JR (2003) Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 98:865-870
29. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A (2004) Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10:PI126-PI131
30. Eliakim R, Rachmilewitz D (1992) Potential mediators in inflammatory bowel disease. Gastroenterology Int 5:48-56
31. Grisham MB (1994) Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859-861
32. Wood AJJ (1996) Inflammatory bowel disease. N Engl J Med 334:841-848
33. Gonçalves E, Almeida LM, Dinis TC (1998) Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: A synergistic interaction? Free Radic Res 29:53-66
34. Ulisse S, Gionchetti P, D'Alo S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C (2001) Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: Effect of probiotic treatment. Am J Gastroenterol 96:2691-2699